Authors: Alexander M. Menzies, John B. A. G. Haanen, Marc S. Ernstoff, John A. Thompson, Petros Grivas, Igor Puzanov, James Larkin, Yinghong Wang, Solange Peters, Michel Obeid

Source: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 8, no. 1, pp. e000604
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Subject Terms: Commentary, autoimmunity, Clinical Decision-Making, Drug-Related Side Effects and Adverse Reactions/immunology, Drug-Related Side Effects and Adverse Reactions/prevention & control, Humans, Immune Checkpoint Inhibitors/administration & dosage, Immune Checkpoint Inhibitors/adverse effects, Neoplasms/drug therapy, Neoplasms/immunology, Neoplasms/mortality, Patient Selection, Progression-Free Survival, Retreatment/adverse effects, Retreatment/methods, Risk Assessment, Severity of Illness Index, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Medicine, business.industry, business, Internal medicine, medicine.medical_specialty, Adverse effect, Immune checkpoint, Cancer, medicine.disease, Immune system, Immune checkpoint inhibitors, Autoimmunity, medicine.disease_cause, Blockade, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1bfdeaac9d6643baaf7613a50edb2a
http://europepmc.org/articles/PMC7295425

Authors: Natalie Köhler, Dominik Marschner, Martina Falk, Sandra Duquesne, Federico Simonetta, Robert S. Negrin, Annette Schmitt-Graeff, Eileen Haring, David Rafei-Shamsabadi, Frank Meiss, Justyna Rawluk, Nora Rebeka Javorniczky, Melanie Boerries, Patrick Marschner, Severin Dicks, Justus Duyster, Robert Zeiser, Konrad Aumann, Kathrin Hanke-Müller, Manching Ku

Source: JCI Insight
JCI Insight, Vol. 5, No 6 (2020) P. 1317

Subject Terms: Research Article, General Medicine, Immunology, Inflammation, medicine.symptom, medicine, Cancer, medicine.disease, business.industry, business, Spleen, medicine.anatomical_structure, Biomarker (medicine), Adverse effect, Cancer immunotherapy, medicine.medical_treatment, Acquired immune system, Immune system, Animals, Antineoplastic Agents, Immunological/adverse effects, Humans, Immune Checkpoint Inhibitors/adverse effects, Mice, Mice, Knockout, MicroRNAs/genetics, Polymorphism, Single Nucleotide

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bddb817444cfc4cfd247a46fdf52174d
https://europepmc.org/articles/PMC7213806/

Authors: Mario Mandala, Paul Lorigan, Matilde De Luca, Andrea Bianchetti, Barbara Merelli, Anna Cecilia Bettini, Lucia Bonomi, Sharon Nahm, Maria Grazia Vitale, Giorgia Negrini, Andrea Di Croce, Paolo Antonio Ascierto, Eliana Rulli, Carlo Alberto Tondini

Source: Mandala, M, Lorigan, P, De Luca, M, Bianchetti, A, Merelli, B, Bettini, A C, Bonomi, L, Nahm, S, Vitale, M G, Negrini, G, Di Croce, A, Ascierto, P A, Rulli, E & Tondini, C A 2021, ' SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors : An observational prospective study ', Journal for ImmunoTherapy of Cancer, vol. 9, no. 2, e001694 . https://doi.org/10.1136/jitc-2020-001694, https://doi.org/https://jitc.bmj.com/content/jitc/9/2/e001694.full.pdf
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)

Subject Terms: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Aged, COVID-19/complications, Female, Gastrointestinal Diseases/chemically induced, Humans, Immune Checkpoint Inhibitors/adverse effects, Male, Middle Aged, Neoplasms/complications, Prospective Studies, SARS-CoV-2/isolation & purification, Survival Rate, Clinical/Translational Cancer Immunotherapy, immunotherapy, melanoma, lung neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898e5bd5d655eff292f81bd89c964284
https://syndication.highwire.org/content/doi/10.1136/jitc-2020-001694

Authors: Hayashi-Tanner Y; Medical Education, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA. Electronic address: yhayashi@gundersenhealth.org., Polewski PJ; Medical Education, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA., Gaddam M; Medical Education, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA., Fisher NR; Medical Research, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA. Electronic address: nancy.fisher@labcorp.com., Kovacs AJ; Medical Research, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA. Electronic address: ajkovacs@gundersenhealth.org., Marinier DE; Hematology and Medical Oncology, Gundersen Health System, 1900 South Ave., La Crosse, WI 54650, USA. Electronic address: demarini@gundersenhealth.org.

Source: Journal of geriatric oncology [J Geriatr Oncol] 2022 Sep; Vol. 13 (7), pp. 1011-1016. Date of Electronic Publication: 2022 May 28.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101534770 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-4076 (Electronic) Linking ISSN: 18794068 NLM ISO Abbreviation: J Geriatr Oncol Subsets: MEDLINE

MeSH Terms: Antineoplastic Agents, Immunological*/adverse effects , Neoplasms*/drug therapy, Aged ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Male ; Progression-Free Survival ; Retrospective Studies